文章预览
Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study Background Trophoblast cell surface antigen 2 (TROP2) is highly expressed in EC and OC. Sac-TMT (also known as MK-2870/SKB264) is a TROP2 ADC developed with a hydrolytically cleavable linker to conjugate a belotecan-derivative topoisomerase I inhibitor. Here, we report the preliminary results from a Phase 2 study in pts with advanced EC and OC (KL264-01, NCT04152499). Methods Advanced EC and OC pts who have been previously treated with platinum-based chemo were given sac-TMT at 5 mg/kg Q2W until disease progression, unacceptable toxicity or withdrawal of consent. Tumor assessment was performed every 8 weeks per RECIST v1.1 by investigator. The TROP2 expression was scored using the semi-quantitative H-score method, and cut-off point was set to 200. Results As of March 5, 2024, 44 EC pts were enrolled and
………………………………
